Framingham {sur}

Framingham Heart Study

Description

The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular disease among a population of non-institutionalized people in the community of Framingham, Massachusetts. The Framingham Heart Study was a landmark study in epidemiology in that it was the first prospective study of cardiovascular disease and identified the concept of risk factors and their joint effects. The study began in 1956 and 5,209 subjects were initially enrolled in the study. In our dataset, we included variables from the first examination in 1956 and the third examination, in 1968. Clinic examination data has included cardiovascular disease risk factors and markers of disease such as blood pressure, blood chemistry, lung function, smoking history, health behaviors, ECG tracings, echocardiography, and medication use. Through regular surveillance of area hospitals, participant contact, and death certificates, the Framingham Heart Study reviews and adjudicates events for the occurrence of any of the following types of coronary heart disease(CHD): angina pectoris, myocardial infarction, heart failure, and cerebrovascular disease.

Usage

Framingham

Format

A data frame with 400 rows and 33 variables:

ID

case number

SEX

sex

TOTCHOL1

serum cholesterol (mg/dL) at initial examination

AGE1

age (years) at initial examination

SYSBP1

systolic blood pressure (mmHg) at initial examination

DIABP1

diastolic blood pressure (mmHg) at initial examination

CURSMOKE1

indicator that participant currently is a cigarette smoker at initial examination

CIGPDAY1

cigarettes smoked per day at initial examination

BMI1

Body Mass Index (kg/(M*M)) at initial examination

DIABETES1

indicator that participant is diabetic at initial examination

BPMEDS1

use of anti-hypertensive medication at initial examination

HEARTRTE1

ventricular rate (beats/min) at initial examination

GLUCOSE1

casual glucose (mg/dL) at initial examination

PREVCHD1

prevalent CHD (angina pectoris, myocardial infarction, or coronary insufficiency) at initial examination

TIME1

days since initial examination

TIMECHD1

days from initial examination to any CHD event

TOTCHOL3

serum cholesterol (mg/dL) at third examination

AGE3

age (years) at third examination

SYSBP3

systolic blood pressure (mmHg) at third examination

DIABP3

diastolic blood pressure (mmHg) at third examination

CURSMOKE3

indicator that participant currently is a cigarette smoker at third examination

CIGPDAY3

cigarettes smoked per day at third examination

BMI3

Body Mass Index (kg/(M*M) at third examination

DIABETES3

indicator that participant is diabetic at third examination

BPMEDS3

use of anti-hypertensive medication at third examination

HEARTRTE3

ventricular rate (beats/min) at third examination

GLUCOSE3

casual glucose (mg/dL) at third examination

PREVCHD3

prevalent CHD (angina pectoris, myocardial infarction, or coronary insufficiency) at third examination

TIME3

days since initial examination at third examination

HDLC3

HDL cholesterol (mg/dL) at third examination

LDLC3

LDL cholesterol (mg/dL) at third examination

TIMECHD3

days from initial examination to any CHD event at third examination

ANYCHD4

indicator of event of hospitalized myocardial infarction, angina pectoris, coronary insufficiency, or fatal CHD by the end of the study

Details

The associated dataset is a subset of the data collected as part of the Framingham study and includes laboratory, clinic, questionnaire, and adjudicated event data on 400 participants. These participants for the dataset have been chosen so that among all male participants, 100 smokers and 100 non-smokers were selected at random. A similar procedure resulted in 100 female smokers and 100 female non-smokers. This procedure resulted in an over-sampling of smokers. The data for each participant is on one row. People who had any type of CHD in the initial examination period are not included in the dataset.